ESC 365 - Heart failure risk stratification and efficacy of dapagliflozin in patients with type 2 diabetes mellitus

ESC Premium Access

Heart failure risk stratification and efficacy of dapagliflozin in patients with type 2 diabetes mellitus

Session: The right glucose-lowering drugs for the right patient

Topic: Pharmacotherapy

Speaker: Doctor D. Berg (Boston, US)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Doctor David Berg

Brigham and Women's Hospital, Boston (United States of America)

2 presentations

0 follower

3 more presentations in this session

State of the Art in antidiabetic treatment to prevent CVD

Speaker: Professor A. Norhammar (Stockholm, SE)

Albuminuria as a predictor of incident ischemic stroke and myocardial infarction in patients with type 2 diabetes but without cardiovascular disease: A Danish cohort study

Speaker: Mrs M. Fangel (Aalborg, DK)

Cardiovascular risk profiles and outcomes in patients with type 2 diabetes - Implications for choice of new diabetes therapies

Speaker: Mrs M. Elmegaard (Copenhagen, DK)

Access the full session

The right glucose-lowering drugs for the right patient

Speakers: Doctor D. Berg, Professor A. Norhammar, Mrs M. Fangel, Mrs M. Elmegaard

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources